Table 1.
Ongoing trials on treatment failure after intravesical BCG immunotherapy.
| Drug | Condition | Phase | Status | Estimated Study Completion Date | Study Number |
|---|---|---|---|---|---|
| Pembrolizumab + BCG | Reccurent high risk or BCG-refractory NMIBC | 1 | Active, not recruiting | February 2022 | NCT02808143 |
| Durvalumab | BCG-refractory NMIBC | 2 | Recruiting | 31 December 2021 | NCT03759496 |
| INSTILADRIN (nadofaragene firadenovec) | BCG-unresponsive NMIBC | 3 | Active, not recruiting | 31 August 2022 | NCT02773849 |
| Durvalumab | BCG-refractory CIS | 2 | Active, not recruiting | 31 December 2021 | NCT02901548 |
| Atezolizumab | BCG-refractory NMIBC | 2 | Recruiting | 31 December 2021 | NCT02451423 |
| Camrelizumab | BCG-refractory NMIBC | 1, 2 | Not yet recruiting | October 2022 | NCT04706598 |
| Erdafitinib | NMIBC recurrence after bacillus Calmette- Guerin (BCG) | 2 | Recruiting | 20 June 2026 | NCT04172675 |
| Atezolizumab | BCG-unresponsive NMIBC | 2 | Active, not recruiting | 1 August 2021 | NCT02844816 |
| Gemcitabine and Pembrolizumab | BCG-unresponsive NMIBC | 2 | Recruiting | 31 March 2023 | NCT04164082 |
| Durvalumab monotherapy Durvalumab + BCG Durvalumab + EBRT |
BCG-relapsing tumour | 1, 2 | Recruiting | 1 March 2023 | NCT03317158 |